Ratings Krsnaa Diagnostics Limited

Equities

KRSNAA

INE08LI01020

Market Closed - NSE India S.E. Other stock markets 03:02:02 2024-05-18 EDT			5-day change	1st Jan Change
599.2 ^INR	+0.17%		+2.37%	-15.13%

04-09	Krsnaa Diagnostics Forms New Wholly-Owned Subsidiary	MT
02-13	Transcript : Krsnaa Diagnostics Limited, Q3 2024 Earnings Call, Feb 13, 2024

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.5 times its estimated earnings per share for the ongoing year.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
KRSNAA DIAGNOSTICS LIMITED	-15.13%	232M	-
SONIC HEALTHCARE LIMITED	-16.99%	8.55B	B+
RADNET, INC.	+65.23%	4.24B	C+
DR. LAL PATHLABS LIMITED	-1.63%	2.54B	B-
SYNLAB AG	-10.68%	2.44B	-
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-41.76%	2.35B	B-
NEOGENOMICS, INC.	-8.53%	1.89B	C-
FLEURY S.A.	-19.29%	1.55B	A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-39.61%	1.23B	C+
METROPOLIS HEALTHCARE LIMITED	+9.54%	1.13B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes